|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The Petach Tikva, Israel-based drugmaker on Dec. 15 launched generic Viread a day after announcing plans to cut 14,000 jobs globally over the next two years as part of restructuring efforts. Here come ...
Teva continued its two-day upswing Friday after announcing the launch of a generic version of a drug from Gilead, a day after the drugmaker unveiled a massive cost-cutting plan.
The FDA approves label expansion of Pfizer's (PFE) JAK inhibitor Xeljanz for two doses on an impressive data from two phase III studies.
Several presentations at the annual meeting of the American Society of Hematology grab headlines in the cancer space.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Novartis AG Here are 5 ETFs with the largest exposure to NVS-US. Comparing the performance and risk of Novartis AG with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) shares have gained almost 15% in value since yesterday after new Danish CEO Kare Schultz's first conference call, where the recovering Israeli pharma giant's leadership unveiled cost cutting plans that outclassed Street-wide expectations. For Koffler, "the punch line" boils down to the giant's strategy to scale back $3 billion in expenses along with a reduction of a quarter of its workforce by 2019 from a projected cost base of $16.1 billion this year. The goal is for over half of this cost cutting, or past $1.5 billion, to be seen through next year.
The FDA could further pressure generic drugmakers in 2018 by continuing along its path of increased generic approvals.
Impressed with the turnaround initiatives at Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA ), an analyst at Credit Suisse upgraded the company's shares . The Analyst Credit Suisse analyst Vamil ...
Shares of Teva Pharmaceuticals (TEVA) are higher on Friday, following a pair of upgrades. The moves come after Teva announced a restructuring plan on Thursday, following the stock's nearly 50% slump since the start of the year. Credit Suisse's Vamil Divan upgraded the stock to Neutral, writing that the company's turnaround looks positive and management is making the right moves--although execution is key.
Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA ) announced Thursday a plan to eliminate more than 25 percent of its worldwide workforce as part of a strategy to slash $3 billion of annual costs. ...
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) announced this morning the exclusive US launch of Viread®1 (tenofovir disoproxil fumarate) tablets 300 mg, a generic version of Gilead Sciences' (NASDAQ:GILD) Viread tablets. Truvada was initially approved by FDA in 2004 to treat HIV in combination with other antiretroviral drugs, and later gained approval as the first drug to prevent sexually transmitted HIV-1 infection in uninfected adults in 2012. Viread®1 received an FDA approval for its Abbreviated New Drug Application (ANDA) in June, granting Teva the right to produce generic Truvada for the combination tablet’s use as a component of an HIV treatment regimen and as pre-exposure prophylaxis (PrEP).
Generic drug prices have been declining all year, posing a crisis for the industry and prompting the very cost-cutting that Teva just announced.
The restructuring is supposed to help turn around the beleaguered company, but could actually hurt it, some Wall Street analysts said.
Shares of Teva Pharmaceutical Industries Ltd. rallied 3.5% in premarket trade Friday, after the drug maker announced the exclusive launch of generic Viread 1 tablets (300 milligrams) in the U.S. The rally ...
The Zacks Analyst Blog Highlights: Microsoft, Johnson & Johnson, ExxonMobil, American Airlines and Honda
Goldman Sachs raises its rating to buy for the generic drugmaker, citing Teva's aggressive cost-cutting targets for the next two years.
This week's pharma sector highlights include ASH data, Teva's restructuring announcement and Lilly's (LLY) 2018 outlook.
U.S. equities fell on Thursday amid doubts over the fate of the GOP’s tax cut plans. The doubt hit investors after a number of Republican senators expressed reservations about the amount of the child tax credit. In the end, the Dow Jones Industrial Average lost 0.3%, the S&P 500 lost 0.4%, the Nasdaq Composite lost 0.3% and the Russell 2000 lost 1.2%.